Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 645-652

  Cheng, Hao ^a   Cao, Xianhua ^a   Xian, Ming ^a,c   Fang, Lanyan ^a   Cai, Tingwei Bill ^a   Ji, Jacqueline Jia ^a   Tunac, Josefino B ^b   Sun, Duxin ^a   Wang, Peng George ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b JJ Pharma Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXY 2,5 BIS(HYDROXYMETHYL)PYRROLIDINE; BETA GALACTOSIDASE; BETA GLUCOSIDASE; CARBOHYDRATE; GELDANAMYCIN; GLUCOSE; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMICAL STRUCTURE; DRUG CONJUGATION; DRUG INHIBITION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; GLYCOSYLATION; HUMAN; HUMAN CELL;

ALKALOIDS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BETA-GALACTOSIDASE; BETA-GLUCOSIDASE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GALACTOSE; HUMANS; IMINO FURANOSES; LACTAMS, MACROCYCLIC; LACTOSE; MANNITOL; PYRROLIDINES; QUINONES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 12344337347     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049693a     Document Type: Article

References (26)

1. DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H. Geldanamycin, a new antibiotic. J. Antibiot. 1970, 23, 442-447.
2. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U. et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
3. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-61.
4. Ferrarini, M.; Heltai, S.; Zocchi, M. R.; Rugarli, C. Unusual expression and localization of heat-shock proteins in human tumor cells. International journal of cancer. J. Int. Cancer 1992, 51, 613-619.
5. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373.
6. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
7. Sausville, E. A. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 7, 2228-2236, 2001. Clin. Cancer Res. 2001, 7, 2155-2158.
8. Sausville, E. A. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 7, 2228-2236, 2001. Clin. Cancer Res. 2001, 7, 2155-2158.
9. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F. et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem. 1995, 38, 3813-3820.
10. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F. et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 1995, 38, 3806-3812.
11. Mandler, R.; Kobayashi, H.; Davis, M. Y.; Waldmann, T. A.; Brechbiel, M. W. Modifications in Synthesis Strategy Improve the Yield and Efficacy of Geldanamycin-Herceptin Immuno-conjugates. Bioconjugate Chem. 2002, 13, 786-791.
12. Kuduk, S. D.; Harris, C. R.; Zheng, F. F.; Sepp-Lorenzino, L.; Ouerfelli, O. et al. Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg. Med. Chem. Lett. 2000, 10, 1303-1306.
13. Kuduk, S. D.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N.; Danishefsky, S. J. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg. Med. Chem. Lett. 1999, 9, 1233-1238.
14. Kasuya, Y.; Lu, Z.; Kopeckova, P.; Kopecek, J. Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems. Bioorg. Med. Chem. Lett. 2001, 11, 2089-2091.
15. Adams, J.; Elliott, P. J. New agents in cancer clinical trials. Oncogene 2000, 19, 6687-6692.
16. Egorin, M. J.; Zuhowski, E. G.; Rosen, D. M.; Sentz, D. L.; Covey, J. M. et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol. 2001, 47, 291-302.
17. Benchekroun, N. M.; Myers, C. E.; Sinha, B. K. Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance. Free Radic. Biol. Med. 1994, 17, 191-200.
18. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl. Cancer Inst. 1999, 91, 1940-1949.
19. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990, 50, 814s-819s.
20. Sung, C.; Dedrick, R. L.; Hall, W. A.; Johnson, P. A.; Youle, R. J. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res. 1993, 53, 2092-2099.
21. Senter, P. D.; Saulnier, M. G.; Schreiber, G. J.; Hirschberg, D. L.; Brown, J. P. et al. Antitumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 4842-4846.
22. Bagshawe, K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 1987, 56, 531-532.
23. Bakina, E.; Farquhar, D. Intensely cytotoxic anthracycline prodrugs: galactosides. Anti-cancer Drug Des. 1999, 14, 507-515.
24. Sherwood, R. F. Advanced drug delivery reviews: enzyme prodrug therapy. Adv. Drug Delivery Rev. 1996, 22, 269-288.
25. Tietze, L. F.; Feuerstein, T.; Fecher, A.; Haunert, F.; Panknin, O. et al. Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug. Angew. Chem., Int. Ed. 2002, 41, 759-761.
26. Ghosh, A. K.; Khan, S.; Marini, F.; Nelson, J. A.; Farquhar, D. A daunorubicin b-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy. Tetrahedron Lett. 2000, 41, 4871-4874.